Cite
HARVARD Citation
Michot, J. et al. (2020). Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Lancet. 7 (9), pp. e649-e659. [Online].